ERBB2 and breast carcinoma: After the treatment of cambogin against a number of cancer cell lines such as HeLa (human cervical carcinoma), HepG2 (human hepatic carcinoma), A549 (human lung carcinoma), HCT116 (human colon carcinoma), SK-BR-3 (ER− PR− HER2+), MCF-7(ER+PR+HER2−), and triple negative breast cancer (TNBC) cell line, MDA-MB-468 (ER− PR− HER2−), it was identified that cambogin was much more adept in showing the best cytotoxicity toward breast cancer cell lines, whereas cambogin was reluctant toward normal HMEC-1 cells at a similar dosage.345